The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

Current Dermatology Reports

Volumn 2, Issue 2, 2013, Pages 84-100

  Pappas Taffer, Lisa ^a   Rosenbach, Misha ^a   Chu, Emily Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acantholytic dyskeratosis; Alopecia; Anti CTLA4; Basal cell carcinoma; BRAF inhibitors; Curly hair; Cysts; Dabrafenib; Grover's disease; Hair depigmentation; Hand foot skin reaction; Ipilimumab; Keratoacanthoma; Keratosis pilaris; Melanoma; Nevi; Palmar plantar hyperkeratosis; Panniculitis; Photosensitivity; Seborrheic dermatitis; Squamous cell carcinoma; Vemurafenib; Verrucous keratoses; Vitiligo

Indexed keywords

B RAF KINASE INHIBITOR; BETAMETHASONE; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; DESONIDE; DIPHENHYDRAMINE; FLUOROURACIL; HYDROXYZINE; IPILIMUMAB; KERATOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POLIDOCANOL; PREDNISONE; SUNSCREEN; TRAMETINIB; TRIAMCINOLONE; VEMURAFENIB;

ACANTHOLYTIC DYSKERATOSIS; ACTINIC KERATOSIS; ALOPECIA; ALOPECIA AREATA; BASAL CELL CARCINOMA; DARIER DISEASE; DEPIGMENTATION; DERMATOLOGIST; DRUG DOSE REDUCTION; EPIDERMOID CYST; ERYTHEMA; HAIR DISEASE; HAIR LOSS; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HYPERSENSITIVITY; KERATOACANTHOMA; MEASLES LIKE RASH; MELANOMA; METAPLASIA; METASTATIC MELANOMA; PANNICULITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEBORRHEIC DERMATITIS; SEBORRHEIC KERATOSIS; SKIN CARCINOMA; SKIN TOXICITY; TRANSIENT ACANTHOLYTIC DERMATOSIS; VITILIGO;

EID: 84890446669     PISSN: None     EISSN: 21624933     Source Type: Journal    
DOI: 10.1007/s13671-013-0039-9     Document Type: Review

References (60)

1. Manousaridis I et al. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatol Venereol. 2013; 27(1): 11-8.
2. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009; 14(8): 848-61.
3. Davies H et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892): 949-54.
4. Platz A et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol. 2008; 1(4): 395-405.
5. Chapman PB et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507-16.
6. Zelboraf ® (vemurafenib) package insert. South Sn Francisco, CA: Genentech USA Inc.; 2012.
7. Hauschild A et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358-65.
8. Flaherty KT et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694-703.
9. •Anforth RM et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012; 167(5): 1153-60. Prospective dermatologic observational study of patients (n=43) enrolled at a single institution in phase I/II dabrafenib trials in Sydney, Australia.
10. Alloo A et al. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol. 2012; 148(3): 363-6.
11. •Sinha R et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012; 167(5): 987-94. Review of cutaneous toxicities and dermatologic cohort of ten patients treated with vemurafenib.
12. •Huang V et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol. 2012; 148(5): 628-33. Cohort of 15 patients treated with vemurafenib.
13. •Chu EY et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012; 67(6): 1265-72. Reported the cutaneous side effects of 14 patients treated with BRAFis.
14. Su F et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366(3): 207-15.
15. Weeraratna AT. RAF around the edges-the paradox of BRAF inhibitors. N Engl J Med. 2012; 366(3): 271-3.
16. Oberholzer PA et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol. 2012; 30(3): 316-21.
17. Lacouture ME et al. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol. 2012; 30(3): 329-30.
18. Harvey NT, Millward M, Wood BA. Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition. Am J Dermatopathol. 2012; 34(8): 822-6. Histologic review of squamoproliferative lesions in cohort of patients treated with BRAFis.
19. Sosman JA et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8): 707-14.
20. Falchook GS et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379(9829): 1893-901.
21. Mattei PL et al. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol. 2012. Retrospective case review of 33 patients treated with BRAFis-15 patinets treated with vemurafenib, 18 patients treated with combination dabrafenib/trametinib.
22. Boyd KP et al. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol. 2012; 67(6): 1375-9. Review of non-malignant skin side effects associated with vemurafenib, providing pictures.
23. Anforth R et al. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res. 2012; 25(5): 569-72. Evaluated frequency of RAS and PIK3CA in verrcous keratosis and cSCC.
24. Long GV et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11): 1087-95.
25. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 365(15): 1448-9. author reply 1450. First author in the literature to report new or evolving atypical nevi and new primary melanomas, found to have wild-type BRAF.
26. •Zimmer L et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012; 30(19): 2375-83. Study evaluating genetic mutations and signal transduction molecule expression in 22 cutaneous melanocytic lesions that were clinically suspcious fro melanoma at seven international melanoma centers in clinical trials 2010-2011. Confirmed all were wild-type BRAF, with increased downstream MAPK pathway activation.
27. Haenssle, H. A., et al., Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib: Importance of Sequential Dermoscopy. Arch Dermatol. 2012; 148(10): 1183-5. First to report three dynamic changes in nevi in a patient with sequential dermoscopy, and also showed the changing nevi or new nevi were wild type BRAF.
28. Dalle, S., et al. Second primary melanomas under vemurafenib. Br J Dermatol, 2012. doi: 10. 1111/bjd. 12093.
29. Fearfield, L., et al. Second perimary melanomas under vemurafenib-reply from the author. Br J Dermatol, 2012. doi: 10. 1111/bjd. 12094.
30. •Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012; 366(5): 480-1. Demonstrated vemurafenib-induced photosensitivity is UVA-mediated, and showed that it can be revered with UVA-blocking sunscreen.
31. •Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012; 366(9): 866-8. Cohort of 12 paitents with sequential ipilimumab then vemurafenib had increased risk for morbilliform eruptions.
32. Novoa RA et al. Vasculitis and panniculitis associated with vemurafenib. J Am Acad Dermatol. 2012; 67(6): e271-2. Two cases of panniculitis without arthralgias, 1 case of vasculitis with ESS.
33. Gupta M et al. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption. Arch Dermatol. 2012; 148(8): 966-8. Case of preexistant Grover's disease that worsened with vemurafenib, complicated by HSV superinfection.
34. Story SG et al. Eccrine squamous syringometaplasia associated with vemurafenib therapy. J Am Acad Dermatol. 2012; 67(5): e208-10. Reported facial papules with eccrine squamous syringometaplasia on biopsy.
35. Pappas-Taffer L, Higgins HW, Robinson-Bostom L, McDonald CJ. Dermatologic toxicities of anticancer therapy. In: Abeloff M, Armitage J, Niederhuber J, Kastan M, McKenna W. Gillies, editors. Abeloff's Clinical Oncology, 5th Edition. Philadelphia, PA: Elsevier; 2012.
36. Zimmer L et al. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol. 2012; 148(3): 357-61. Reported two cases of panniculitis with arthralgias.
37. Infante J, F. G., Lawrence D, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK 212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract 8503]. J Clin Oncol, 2011; 29 (suppl). Case of panniculitis in the setting of combination BRAF/MEK inhibitor.
38. Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol. 2008; 59(3): 524-9.
39. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8): 711-23.
40. TM (ipilimumab) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2012.
41. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30(21): 2691-7.
42. •Jaber SH et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol. 2006; 142(2): 166-72. Morbilliform eruption noted prospectively in a cohort of 63 patients receiving monotherapy ipilimumab.
43. Zimmer L et al. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges. 2012; 10(7): 475-86.
44. Weber J et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15(17): 5591-8.
45. Wolchok JD et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010; 11(2): 155-64.
46. O'Day SJ et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21(8): 1712-7.
47. Pavlick AC OP, Kannan R, Madden KM, et al. Hair depigmentation as an indicator of durable response to CTLA-4 therapy. J Clin Oncol. 2010; 28. doi: 15s. (suppl; abstact 8571). Reported the occurance of hair depigmentation, often resulting in diffuse vitiligo, among a cohort of patients treated with anti-CTLA4 monoclonal antibody therapy.
48. Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011; 9(4): 277-86.
49. Gutzmer R et al. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int. 2012; 109(8): 133-40.
50. Lim JL, Dahiya M, Burgin S. Intertriginous and follicular eruption to anticytotoxic T-lymphocyte antigen 4 monoclonal antibody. J Am Acad Dermatol. 2008; 59(2 Suppl 1): S60-1. Case report of eruption with ipilimumab and histologic findings.
51. Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res. 2012; 4: 299-307.
52. Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26): 2517-26.
53. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Seminars in Oncology. 2010; 37(5): 499-507.
54. Sibaud V et al. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Ann Chir Plast Esthet. 2012; 57(2): 106-13.
55. Flaherty KT et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9): 809-19.
56. Margolin K. Ipilimumab in a phase II trial of melanoma patients with brain metastases. Oncoimmunology. 2012; 1(7): 1197-9.
57. Beck KE et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006; 24(15): 2283-9.
58. Viros, A., et al. Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor-Induced Cutaneous Squamous Cell Carcinoma. J Invest Dermatol. 2012; 133: 274-76.
59. Anforth R et al. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol. 2012; 30(19): e165-7.
60. Fox MC et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: management of stage IV disease. J Am Acad Dermatol. 2013; 68(1): 13 e1-13 e13.